Compare NBN & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | ODTX |
|---|---|---|
| Founded | 1872 | 2021 |
| Country | United States | United States |
| Employees | 225 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | 2025 |
| Metric | NBN | ODTX |
|---|---|---|
| Price | $125.01 | $19.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $145.50 | $35.33 |
| AVG Volume (30 Days) | 93.9K | ★ 228.1K |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.75 | $15.10 |
| 52 Week High | $142.31 | $29.05 |
| Indicator | NBN | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 46.77 |
| Support Level | $121.69 | $15.73 |
| Resistance Level | $126.68 | $19.60 |
| Average True Range (ATR) | 3.75 | 1.35 |
| MACD | 0.25 | 0.31 |
| Stochastic Oscillator | 17.32 | 65.85 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The bank conducts its loan-related activities through two primary channels: the National Lending Division and the Small Business Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans; consumer loans; and small business administration loans, among others. Additionally, the bank provides telephone banking, online banking, mobile banking, and remote deposit capture services, and other banking products and services. The majority of its revenue is derived in the form of interest and dividends.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.